AOD-9604

Mechanism of action

AOD-9604 is a modified 16-amino-acid peptide corresponding to the C-terminal region of human growth hormone (hGH residues 177–191 with an additional N-terminal tyrosine). Its development was premised on the observation that the lipolytic activity of hGH could be separated from its growth-promoting and insulin-like properties, which are principally mediated through GH receptor binding in the N-terminal and mid-molecule regions. The full GH receptor (GHR) binding domain overlaps primarily with hGH amino acids 1–53 and specific residues in the central alpha-helix. AOD-9604 lacks these receptor-binding determinants and therefore does not engage GHR to a degree that produces meaningful IGF-1 stimulation. This was confirmed in clinical pharmacology studies during the Metabolic Pharmaceuticals obesity programme, where repeated subcutaneous dosing with AOD-9604 over 12 weeks did not elevate serum IGF-1 or IGF-binding proteins. Fasting glucose, insulin, and HbA1c also remained unchanged, distinguishing AOD-9604 from recombinant hGH, which causes insulin resistance and hyperglycaemia at pharmacological doses. In adipocyte research, AOD-9604 increases lipolysis through β3-adrenergic receptor (β3-AR) sensitisation and direct effects on the cyclic-AMP/protein kinase A (cAMP/PKA) pathway downstream of membrane receptors in adipocytes. In differentiated 3T3-L1 adipocyte cultures (Heffernan et al., Endocrinology 2007), AOD-9604 stimulated glycerol release (a marker of triglyceride hydrolysis) and reduced triglyceride accumulation in cells simultaneously undergoing differentiation. The mechanism is thought to involve enhanced responsiveness of β3-AR to catecholamine stimulation, but the precise molecular target of AOD-9604 on adipocytes has not been fully characterised. The cartilage-repair angle emerged from observations that the hGH C-terminal region contains sequences involved in proteoglycan synthesis and chondrocyte anabolism independent of IGF-1. Pre-clinical studies demonstrated that intra-articular AOD-9604 stimulated glycosaminoglycan synthesis in chondrocyte cultures and reduced cartilage degradation markers in surgically induced osteoarthritis models. The combination of AOD-9604 with hyaluronic acid has been explored as an intra-articular therapy for osteoarthritis, with positive outcomes in rabbit models, though clinical data in humans remain very limited. A proposed mechanism in cartilage involves activation of TGF-β-independent proteoglycan synthesis pathways and modulation of MMP activity, but these have not been as rigorously characterised as the adipocyte data. The cartilage-focused research is considerably younger and mechanistically less well-defined than the lipolysis work.

Phase IIb clinical trials in obese human subjects demonstrated that repeated subcutaneous and oral AOD-9604 administration over 24 weeks produced no measurable changes in IGF-1, fasting glucose, or insulin sensitivity, firmly establishing the pharmacological separation of the GH C-terminal lipolytic domain from the growth-promoting, diabetogenic GH receptor–IGF-1 axis.

— Notable finding

Research history

AOD-9604 was developed in the late 1990s by researchers at Monash University, Melbourne, in collaboration with Metabolic Pharmaceuticals Ltd, originally under the premise of dissociating the lipolytic from the growth-promoting properties of human growth hormone. The rationale was compelling: hGH causes meaningful weight loss in growth-hormone-deficient subjects, but its clinical use in obesity was restricted by significant side effects including insulin resistance, fluid retention, and concerns about cancer risk associated with supraphysiological IGF-1 levels. If the lipolytic domain could be identified and delivered as an isolated peptide without triggering GHR-IGF-1 signalling, a safer anti-obesity agent was theoretically achievable. The peptide progressed through Phase I and Phase IIb human clinical trials in overweight and obese subjects conducted primarily in Australia and the United States during the late 1990s and early 2000s. Phase IIb results were mixed; AOD-9604 produced modest weight loss and showed a clean safety profile regarding IGF-1, glucose, and insulin, but did not demonstrate the magnitude of weight reduction required for regulatory approval. Phase III was not pursued for the obesity indication by Metabolic Pharmaceuticals, and the obesity programme effectively concluded without approval. In 2014, the Australian Therapeutic Goods Administration (TGA) classified AOD-9604 as a 'novel food ingredient' under Australian food-standards legislation, an unusual regulatory pathway that reflected the compound's low toxicity profile and its presence in some nutritional formulations at the time. This classification created regulatory ambiguity that was widely discussed in the anti-ageing and sports-medicine communities, and it did not extend to jurisdictions outside Australia, including the United Kingdom. The compound attracted attention from the sports world following the AFL Essendon Football Club controversy in 2011–2013, in which AOD-9604 was among substances reportedly administered to players. Australian anti-doping proceedings and WADA deliberations on the compound raised its profile considerably. Separately from the human performance use, academic research into AOD-9604's cartilage-repair properties has continued, with studies from South Korean groups examining intra-articular injection in osteoarthritis models.

Summarised studies

Safety profile

AOD-9604 has a relatively well-characterised short-term human safety profile by the standards of research peptides, owing to its passage through formal Phase I and Phase IIb clinical trials. In Phase I studies, single doses up to 1 mg/kg intravenously and repeated daily subcutaneous doses over 12 weeks were generally well tolerated. There were no clinically significant effects on IGF-1, glucose tolerance, insulin sensitivity, lipid profiles, thyroid function, or cortisol — the hormonal safety parameters of most concern when manipulating the GH axis. No serious adverse events were attributed to the peptide in published trial reports. At the site of subcutaneous injection, mild transient reactions including erythema, induration, and pruritus were reported in a minority of subjects. Systemic adverse events did not differ significantly from placebo in controlled periods. The most important safety caveat for ongoing research is the absence of long-term human data beyond 12–16 weeks of continuous administration. Potential effects of sustained β3-AR sensitisation on cardiac tissue (where β3-AR is also expressed and modulates contractility) have not been characterised in the context of AOD-9604. Immunogenicity studies for anti-peptide antibody induction over longer periods have not been published. For intra-articular research use, the safety considerations of the joint-injection procedure itself — sterility, volume, and carrier — are as important as any peptide-specific toxicology. Human intra-articular AOD-9604 data are extremely limited.

UK regulatory status

AOD-9604 is not licensed for any therapeutic indication by the UK Medicines and Healthcare products Regulatory Agency (MHRA). It has not received marketing authorisation in the UK, EU, or United States. Australia's TGA classification as a 'novel food ingredient' in 2014 is specific to Australian food-standards legislation and does not confer any regulatory status in the United Kingdom. The WADA position on AOD-9604 has been complex. The compound is not listed by its specific name on the annual WADA Prohibited List in the same way that established substances appear, but WADA's broader category S2 ('Peptide hormones, growth factors, related substances and mimetics') could be interpreted to encompass growth hormone fragments and analogues. Anti-doping proceedings following the Essendon AFL controversy involved consideration of whether AOD-9604 fell within WADA's scope; outcomes varied across different proceedings. Athletes and researchers associated with competitive sport should consult the current WADA Prohibited List and seek specific legal advice on AOD-9604's status. Research-laboratory possession of AOD-9604 in the UK is unrestricted. It is not a controlled drug under the Misuse of Drugs Act 1971. Clinical or therapeutic administration to humans without MHRA authorisation is not permitted. No MHRA enforcement actions against AOD-9604 specifically have been publicly disclosed.

Frequently asked questions